Soleno Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
VYKAT XR's launch has exceeded expectations with strong revenue, broad payer coverage, and high prescriber engagement. Expansion into new indications and international markets is underway, with a focus on education and community partnerships to drive growth.
-
Achieved 10% market penetration with strong prescriber adoption and stable discontinuation rates. Revenue growth is driven by active patient build and favorable reimbursement, while international expansion and new indications are key strategic priorities.
Fiscal Year 2025
-
VYKAT XR's launch drove $190.4M in 2025 revenue and profitability, with 1,250 patient start forms and 859 active patients. EU approval for DCCR is expected mid-2026, and expansion into GSD I is planned. Strong cash reserves support ongoing growth.
-
VYKAT XR's launch has captured 10% of the TAM in six months, with strong market access and broad prescriber engagement. Education initiatives and support programs are driving ongoing uptake, while safety and regulatory profiles remain consistent with expectations.
-
VYKAT XR, the first FDA-approved treatment for Prader-Willi syndrome, has seen rapid adoption, robust reimbursement, and strong financial performance. Clinical data confirm significant efficacy and manageable safety, with European expansion and patent protection through 2035.
-
Q3 saw doubled revenue, profitability, and strong patient access, with 10% of the addressable market reached in six months. Patient growth is expected to continue, supported by robust payer coverage and positive real-world efficacy and safety. EU expansion is progressing, with a decision on partnering or self-launch pending.
-
Revenues doubled to $66 million with strong cash flow and 10% market penetration in six months. Physician education and peer programs are expanding adoption, while a $100 million buyback signals confidence. European launch is on track for Q2, with regulatory progress and initial focus on Germany.
-
Q3 2025 saw net revenue more than double to $66M and the first profitable quarter, driven by strong VYKAT XR adoption and broad payer coverage. Discontinuation rates rose slightly after a short seller report, but patient and prescriber growth remained robust.
-
Following FDA approval, the new Prader-Willi syndrome drug saw rapid adoption, with strong physician and patient enthusiasm, low discontinuation rates, and a robust safety profile. The company is well-capitalized, expects steady growth, and is preparing for European expansion.
-
A newly launched therapy for Prader-Willi syndrome has seen strong early U.S. uptake, with expanding insurance coverage and promising long-term benefits. The company is financially robust, planning further European expansion, and expects reimbursement hurdles to ease by mid-2026.
-
VYKAT XR's commercial launch drove $32.7M in Q2 revenue, with 646 patient starts and rapid payer coverage (33% of insured lives). Cash position exceeds $500M post-offering, supporting U.S. and EU expansion, while early launch momentum is expected to normalize.
-
VYKAT XR, the first FDA-approved treatment for hyperphagia in PWS, launched with strong clinical efficacy and a clean safety profile. Early commercial uptake is robust, supported by a focused field force, payer engagement, and a solid financial position.
-
The meeting covered director elections and auditor ratification, with both proposals approved by majority vote. No shareholder nominations or questions were raised, and final results will be reported in official filings.
-
VYKAT XR, the first approved treatment for hyperphagia in PWS, demonstrated robust efficacy and safety in a comprehensive clinical program. Early launch metrics show broad adoption, with a strong commercial and payer strategy in place. Patent protection extends into the late 2030s.
-
FDA approved VYKAT XR for PWS hyperphagia, with a rapid U.S. launch and strong early demand—268 start forms and 131 prescribers in 29 days. No Q1 revenue, but a solid cash position supports ongoing commercialization and European expansion.
-
FDA approved VYKAT XR as the first treatment for hyperphagia in PWS patients aged four and older, based on strong phase 3 data and a favorable safety profile. Launch preparations include broad payer engagement, a dedicated field team, and support programs, with commercial rollout expected to accelerate in 2025.
-
DCCR for Prader-Willi syndrome is under FDA priority review with a March 2024 PDUFA date. Clinical data show significant efficacy in hyperphagia and behavior, with commercial launch preparations well advanced and pricing expected in the $360,000–$370,000 range.
-
PDUFA was delayed to March 27 due to logistics, with no major regulatory issues identified. Launch preparations are on track, targeting a May commercial rollout and a market of about 10,000 eligible patients. European submission is planned for the first half of the year.
Fiscal Year 2024
-
FDA extended the PDUFA date to March 27 for further review, focusing on PWS patients aged four and above with hyperphagia. The U.S. market has about 10,000 diagnosed patients. Commercialization plans include a 30-person sales force, strong advocacy, and pricing between $140K and $540K annually, with solid cash supporting the launch.
-
DCCR for PWS has shown significant clinical benefits and is under FDA Priority Review, with a PDUFA date in December 2024. Commercial launch preparations are advanced in the U.S., with European regulatory submission planned for H1 2025 and strong IP protection supporting long-term exclusivity.
-
FDA review is progressing with no expected delays for the December 27th PDUFA date, and labeling discussions are anticipated soon. Market access and payer feedback are positive, with strong demand from patients and physicians, and launch preparations are underway for both U.S. and Europe.
-
FDA accepted the NDA for DCCR with priority review and a December PDUFA date, as the company prepares for a potential launch with expanded commercial teams and strong advocacy support. The rare disease community is highly engaged, and global expansion is planned for next year.
-
The company is advancing a once-daily oral therapy for Prader-Willi syndrome, showing significant improvements in hyperphagia, behavior, and body composition in clinical trials. Regulatory filing is imminent, with strong patent protection and a focused commercial strategy targeting a rare disease market of up to 20,000 U.S. patients.
-
The meeting covered director elections, auditor ratification, and equity plan amendments. All proposals passed by majority vote, with Dr. Andrew Sinclair re-elected as Class 1 Director and Marcum LLP ratified as auditor for 2024.